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Abstract 
Objectives: The aim of the study was to describe the experience with high-frequency 
oscillatory ventilation (HFOV) in a Portuguese Pediatric Critical Care Unit, and to evaluate 
whether HFOV allowed improvement in oxygenation and ventilation.
Methods: This was a retrospective observational cohort study of children ventilated 
by HFOV between January, 2002 and December, 2011. The following parameters were 
recorded: demographic and clinical data, and blood gases and ventilatory parameters 
during the first 48 hours of HFOV.
Results: 80 children were included, with a median age of 1.5 months (min: one week; 
max: 36 months). Pneumonia (n = 50; 62.5%) and bronchiolitis (n = 18; 22.5%) were the 
main diagnoses. Approximately 40% (n = 32) of the patients developed acute respiratory 
distress syndrome (ARDS). Conventional mechanical ventilation was used in 68 (85%) 
of patients prior to HFOV. All patients who started HFOV had hypoxemia, and 56 (70%) 
also presented persistent hypercapnia. Two hours after starting HFOV, a significant 
improvement in SatO2/FiO2 ratio (128 ± 0.63 vs. 163 ± 0.72; p < 0.001) that was sustained 
up to 24 hours of HFOV and a decrease in FiO2 were observed. Since the beginning of 
HFOV, the mean PCO2 significantly decreased (87 ± 33 vs. 66 ± 25; p < 0.001), and the 
pH significantly improved (7.21 ± 0.17 vs. 7.32 ± 0.15; p < 0.001). Overall survival was 
83.8%.
Conclusions: HFOV enabled an improvement in hypercapnia and oxygenation. It is a safe 
option for the treatment of ARDS and severe small airway diseases. 
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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Ventilação oscilatória de alta frequência em crianças: uma experiência de 10 anos
Resumo 
Objetivos: O objetivo do estudo foi descrever a experiência com ventilação oscilatória 
de frequência (VOAF) em uma unidade portuguesa de Cuidados Intensivos Neonatais e 
Pediátricos e avaliar se a VOAF permitiu uma melhoria na oxigenação e na ventilação.
Métodos: Estudo de coorte retrospectivo observacional em crianças submetidas À ven-
tilação com VOAF entre janeiro de 2002 e dezembro de 2011. Os seguintes parâmetros 
foram registrados: dados demográficos e clínicos; gases sanguíneos; e parâmetros venti-
latórios durante as primeiras 48 horas de VOAF.
Resultados: O estudo incluiu 80 crianças com uma idade média de 1,5 mês (mínima: uma 
semana; máxima: 36 meses). Pneumonia (n = 50; 62,5%) e bronquiolite (n = 18; 22,5%) 
foram os principais diagnósticos. Cerca de 40% (n = 32) dos pacientes desenvolveram a 
síndrome da angústia respiratória aguda (SARA). A ventilação mecânica convencional 
foi utilizada em 68 (85%) pacientes antes da VOAF. Todos os pacientes que começaram 
a VOAF tiveram hipoxemia, e 56 (70%) também apresentaram hipercapnia persistente. 
Duas horas após o início da VOAF, foi observada uma melhoria significativa na proporção 
SatO2/FiO2 (128 ± 0,63 em comparação a 163 ± 0,72; p < 0,001), que foi mantida durante 
as 24 horas de VOAF, e uma redução da FiO2. Desde o início da VOAF, a PCO2 média teve 
uma queda significativa (87 ± 33 em comparação a 66 ± 25; p < 0,001) e o pH aumentou 
significativamente (7,21 ± 0,17 em comparação a 7,32 ± 0,15; p < 0,001). A sobrevida 
geral foi de 83,8%.
Conclusões: A VOAF permitiu uma melhoria na hipercapnia e na oxigenação. Trata-se 
de uma opção segura no tratamento da SARA e de doenças graves das pequenas vias 
aéreas.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. 
Introduction
Acute respiratory failure is a frequent problem in children 
admitted to pediatric intensive care units (PICUs). It is 
well known that mechanical ventilation is associated with 
barotrauma, volutrauma, atelectrauma, and biotrauma.1-4 
Avoiding ventilator-induced lung injury has become a 
major concern when considering which ventilatory strategy 
to apply to patients with lung diseases. High frequency 
oscillatory ventilation (HFOV) is a lung-protective 
ventilatory mode that ensures alveolar recruitment and 
an optimal lung volume.5,6 During HFOV, very small tidal 
volumes (1-2 mL/kg), high flow rates, and frequencies of 
240-900 cycles per minute are used to open the lung, in 
order to avoid high peak airway pressures, alveolar over 
distension, and repeated cycles of recruitment.5 HFOV 
has been most studied in the context of acute respiratory 
distress syndrome (ARDS), and several studies have 
demonstrated its safety as a lung volume recruitment 
strategy.7-9 However, there isn’t enough evidence to 
support the use of HFOV over conventional mechanical 
ventilation (CMV). To a lesser extent, HFOV has been 
applied in children with air leak or small airway disease, 
such as bronchiolitis.10-14
This study aimed to describe the authors’ experience 
using HFOV in pediatric patients, and to evaluate its effect 
on oxygenation, ventilation, and associated complications. 
This study was based on retrospective analysis of the 
patients treated at the PICU of Hospital Professor Doutor 
Fernando Fonseca in Amadora, Portugal.
Materials and methods
Design
This was an observational retrospective study from January, 
2002 to December, 2011. The study was performed in an 
eleven-bed PICU of a Portuguese hospital with maximum 
capacity for six ventilated patients. The PICU is localized 
in the metropolitan area of Lisbon, which has 800,000 
inhabitants, and admits approximately 500 children yearly. 
This study was approved by the institutional review 
board. 
Patients and data collection
All patients that needed HFOV during the study period were 
considered eligible, except those who were ventilated on 
HFOV due to diaphragmatic hernia. 87 patients were initially 
eligible, but seven were excluded due to insufficient 
clinical data. Data was collected through patient chart 
review. The following data was recorded: demographic, 
diagnosis, maximal ventilatory settings during CMV, and 
hemodynamic status. Blood gases (pH and mean partial 
pressure of carbon dioxide (pCO2), fraction of inspired 
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oxygen (FiO2), transcutaneous oxygen saturation (Sat. 
O2), and ventilator settings of HFOV (mean continuous 
distending airway pressure [Paw], amplitude [delta-p] and 
frequency [Hz]) were recorded immediately before and at 
2, 6, 12, 24 and 48 hours of HFOV.
Maximal parameters during HFOV were considered as the 
highest ventilatory settings observed during six consecutive 
hours. Lung recruitment pressure was defined as the 
maximal mean airway pressure that allowed a stepwise 
decrease of FiO2 until reaching 0.6.
ARDS was defined according to the American-European 
Consensus Conference on ARDS.15 Airway obstructive 
disease as bronchiolitis was defined as a respiratory 
disorder in children until two years of age with rhinitis, 
cough, tachypnea, wheezing, crackles, and use of 
accessory muscles, with or without fever and without 
consolidation on the X-ray. Pneumonia was defined 
as infiltrates on chest X-ray, in addition to one of the 
following: deterioration in pulmonary gas exchange, 
fever (temperature above 38 ºC), white blood cell count 
above 12.000/mm3, or a positive tracheal aspirate 
culture. Sepsis was defined according to the guidelines 
of the Surviving Sepsis Campaign. Multiple organ failure 
was considered when at least two of the following 
organ dysfunctions occurred: central nervous system, 
cardiovascular, hepatic, respiratory, gastrointestinal, 
renal, or hematologic.
High frequency oscillatory ventilation protocol
The ventilatory modes used in CMV (Servoi®, Maquet Inc 
– Wayne, United States and Servo 300 Siemens Medical 
Systems – Solna, Sweden) were pressure control or 
pressure-regulated volume target. The authors opted to 
use CMV with non- aggressive settings (PIP < 30 cmH2O, 
tidal volume < 8 mL/kg, respiratory rate [RR] < 50/min). 
When refractory hypoxemia, defined as Sat.O2 below 90% 
with FiO2 1 or hypercapnia with severe acidosis (pH < 7.22 
and pCO2 > 80 mmHg) occurred, patients were switched 
to HFOV.
Sensor-Medics 3100A® (Sensor Medics Corporation 
– Yorba Linda, CA, USA) was used for HFOV. An “open 
lung strategy” was adopted. The initial settings were 
FiO2 of 1.0, oscillation frequency of 10-12 Hz, a percent 
inspiratory time of 33%, and bias flow of 20-30 L/
min. The Paw was set 5 cmH2O above the mean airway 
pressure during CMV, and increments of 1 cmH2O were 
used until an optimal lung volume was reached, avoiding 
over distension and atelectasis. The oxygenation target 
was an adequate SatO2 (≥ 90%) with FiO2 ≤ 0.6. The 
delta-p was initially set to achieve chest wall vibration 
to the level of thigh in infants, or to the umbilical level 
in newborns. The frequency and delta-p were adjusted 
to obtain an adequate pCO2 and pH above 7.25. General 
supportive care included fluid restriction to 80% of daily 
needs, nutritional support, and antibiotics if needed. 
All patients were sedated with continuous infusion of an 
opioid (morphine), and a benzodiazepine (midazolam). 
Neuromuscular blockage agents were only used when 
there was a significant clinical deterioration related to 
spontaneous activity. Inotropic support, nitric oxide, 
and chest tube drainage were used if necessary. The 
weaning process from HFOV was started when FiO2 
was below 0.4. During this process, Paw was gradually 
decreased by 1-2 cmH2O until a value below 14 cmH2O 
was reached. After HFOV, patients started CMV (support 
mode), non-invasive ventilation, or nasal cannula 
oxygen. 
Outcome measures
The primary outcome was to evaluate whether HFOV 
allowed improvement in oxygenation and ventilation. An 
improvement in oxygenation was considered if a decrease 
in FiO2 allowed Sat.O2 above 90%, and the ratio of Sat.
O2/FiO2 increased along the study period.
16 Evaluation 
of ventilation was performed through changes of pH and 
pCO2 values obtained from capillary blood samples. HFOV 
success was defined as improvement in oxygenation and 
ventilation. HFOV failure was considered when death or 
intractable hypoxemia occurred. 
The secondary outcomes were: a) to study complications 
related to HFOV and mortality rate. A new air leak, 
hypotension, hypoxemia or bradycardia during HFOV were 
considered as complications possibly related to HFOV; b) to 
compare clinical, blood gases, and therapeutic parameters 
in surviving and non-surviving patients; and c) to analyze 
predictive factors of mortality.
Statistical analysis
Quantitative variables were analyzed using measures 
of central location (mean and median) and dispersion 
(standard deviation). Qualitative or categorical variables 
were described as frequencies. To compare quantitative 
variables, Student’s t-test or Wilcoxin’s non-parametric 
test were used, depending on the distribution according 
to normality. Dichotomous variables were studied with 
the chi-squared test or Fisher’s exact tests. A multivariate 
analysis was performed using binary logistic regression 
through the Enter method. All tests were two-tailed, and 
a p-value < 0.05 was considered as significant. Statistical 
analyses were performed using the Statistical Package for 
Social Sciences (SPSS Inc. – Chicago, Illinois, USA) version 
18.0 for Windows. 
Results
Demographics
Eighty patients were included in the study. The median age 
was 1.5 months (1 week-36 months), and 41 (51.3%) were 
male. Most children (n = 38; 47.5%) were ventilated between 
January and March. The median PICU hospitalization was 
15 days (4-105 days). Pneumonia was the most frequent 
diagnosis, present in 50 (62.5%) children. Other diagnoses 
were bronchiolitis in 18 (22.5%), and sepsis in 10 (12.5%) 
patients. Approximately 40% of the patients (n = 32) 
developed ARDS before the institution of HFOV. Table 1 
shows patient’s demographic characteristics, underlying 
diseases, and diagnoses.
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Ventilatory characteristics
CMV was performed in 68 (85%) of patients prior to HFOV, 
and non-invasive ventilation was the first option in 33 
(44%) patients. The median time on CMV before HFOV was 
12 hours (1-360 h). Maximum parameters during CMV were 
(mean±SD): PEEP 6±1 cmH2O, PIP 26±6 cmH2O, RR 52±8 
cpm, and FiO2 0.70±0.25. 
Immediately before starting HFOV, the median Sat.
O2/FiO2 ratio was 156 (43-376) and the median value of 
PCO2 was 82.3 torr (31-200). Before HFOV, four patients 
presented a clinical deterioration due to pulmonary air leak 
(pneumothorax, n = 3; pulmonary interstitial emphysema, n 
= 1). HFOV was initiated based on hypercapnia in 56 (70%), 
hypoxemia with hypercapnia in 13 (16.3%), and hypoxemia 
without hypercapnia in 11 (13.8%) patients. HFOV was 
performed for a median time of 103 hours (12-576 h). The 
median of the highest parameters used during HFOV were: 
FiO2 0.8 (0.3-1), Paw 19 cmH2O (14-44 cmH2O), and delta-p 
50 (30-93). The median frequency used was 10Hz (5-12 
Hz). A median Paw of 19.5 cmH2O (15-44 cm2O) was used to 
perform lung recruitment. All patients were sedated with 
morphine and midazolam. Inotropic support was needed 
in 52 (65%) patients before starting HFOV. Dopamine was 
used alone in 29 (36%) patients, and two or more inotropics 
were needed in 18 (22.5%) cases. 22 (27.5%) patients were 
curarized for a median time of 60 hours (24-960 h). Nitric 
oxide was administered to 14 (17.5%) children.
Primary outcome
With HFOV, immediate and significant increase was 
achieved in the Sat.O2/FiO2 ratio (128±0.63 vs. 163±0.72; p 
< 0.001) that was sustained until 24 hours of HFOV. A FiO2 
of approximately 0.6 was reached after 6 hours of HFOV. 
Immediately after starting HFOV, mean PCO2 significantly 
decreased (87±33 vs. 66±25; p < 0.001) and remained 
within target ranges during the entire study period. 
Also, pH significantly improved at the beginning of HFOV 
(7.21±0.17 vs. 7.32±0.15; p < 0.001), and remained within 
normal values during the 48 hours of the study. Figure 1 
shows blood gases, FiO2, and Sat.O2/FiO2 ratios during the 
study period.
According to the protocol design, during the first two 
hours of HFOV an increment of Paw (17.8±3.5 vs. 18.0±3.4; 
p = 0.03) was observed to reach lung recruitment. After this 
time, significant oscillations in Paw were not registered. 
Significant variations of delta-p and frequency during the 
study were not observed. Table 2 shows ventilator settings 
and hemodynamic parameters during the 48 hours.
Mean arterial pressure did not show significant oscillations 
during the 48 hours studied. After 12-hours of HFOV, a 
significant decrease was observed in heart rate (149±21 vs. 
141±23; p < 0.001). At 24 and 48-hours the heart rate was 
significantly lower (Table 2).
37 (46.3%) patients were successfully weaned from 
HFOV: 25 to non-invasive ventilation, and 12 directly 
to supplementary oxygen through face masks or nasal 
cannula. 
Secondary outcome
During HFOV, seven patients presented with a new air 
leak related to central line insertion (two patients), 
to high-pressure hand-mask ventilation (two patients), 
and to fatal ARDS (three patients). HFOV did not cause 
worsening of pneumothorax in those patients with a 
diagnosis of air leak prior to HFOV. Endotracheal tube 
suction was associated with transitory hypoxemia and/
or bradycardia in 16 (20%) patients. During the course of 
HFOV, reintubation was needed in eight (10%) patients 
due to endotracheal tube obstruction or accidental 
extubation. Most patients (n = 51; 63.8%) did not present 
complications during HFOV.
Overall survival was 83.8% (67 patients). Five patients 
died from multi-organ failure, four from cardiac failure 
(hypoplastic left heart syndrome), and four from both 
septic shock and refractory respiratory failure. Children 
who died had a median age of 4 months (min = 1; max = 
36 months), and were significantly older than those who 
survived, who presented a median age of 1 month (min 
= 9 days; max = 35 months) (p = 0.015). A relevant past 
medical history was more prevalent in the group of non-
survivors (77% vs. 36%; p = 0.006). Also, in this group, 
mechanical ventilation before HFOV was performed for 
a significantly longer period when compared to survivors 
(72±106 vs. 24±39; p = 0.01). Differences in ventilator 
settings during HFOV between both groups are shown in 
Table 3. Non-survivors presented a lower Sat.O2/ FiO2 
ratio (133±60 vs. 104±78; p = 0.006) since the beginning 
of HFOV when compared to survivors. This difference 
was observed during the 48 hours of the study period. 
Values of pH and PCO2 were similar between both groups 
up to 24 hours of HFOV. After that time, a significant 
improvement was observed only in the group of survivors 
Table 1 Patient demographics, underlying diseases, and 
ARDS.
Variable 
Weight (kg), mean±SD 4.1±2.1
Past medical history 
Prematurity, n (%) 25 (31.3)
Cardiac disease, n (%) 7 (8.8)
Neurological disease, n (%) 7 (8.8)
AIDS, n (%) 1 (1.3)
Irrelevant, n (%) 40 (50)
Diagnosis 
Pneumonia, n (%) 50 (62.5)
Bronquiolitis, n (%) 18 (22.5)
Pneumonia with sepsis, n (%) 10 (12.5)
Cardiac insufficiency, n (%) 2 (2.5)
ARDS, n (%) 32 (40)
Multiorgan failure, n (%) 15 (18.8)
AIDS, acquired immunodeficiency syndrome; ARDS, acute 
respiratory distress syndrome; SD, standard deviation.
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(7.40±0.10 vs. 7.30±0.08; p = 0.003). During HFOV, lower 
frequencies and higher Paw and delta-p were used in the 
group of patients who died (p < 0.05) (Table 3). In the 
univariate analysis, predictive factors of mortality were: 
pH and PCO2 at 2 hours, pH at 24-hours, and Sat.O2/
FiO2 ratios at 2 hours, 6 hours, 12 hours, 24 hours, and 
48 hours. In the multivariate analysis, these were not 
independent factors.
Table 2 Mean ventilator settings, gas exchange, blood pressure, and heart rate of the study population at multiple time 
intervals during HFOV.
Parameters At beginning  2 hours 6 hours 12 hours 24 hours 48 hours p-value
 HFOV Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD  
 Mean±SD
Ventilator settings       
Paw (cmH2O),  17.8±3.5 18.0±3.4 18.1±3.1 18.1±3.1 17.8±4.3 17.6±4.5 
a
delta-p 45±12 45±12 45±12 46±13 44±15 45±17 ns
Frequency (Hz) 10±1 10±1 10±1 10±1 10±1 10±1 ns
Hemodynamic data       
Mean arterial pressure 48±11 48±10 50±12 48±13 49±9 51±11 b
Heart rate (cpm) 145±23 145±22 149±21 141±23 136±18 129±17 c
delta-p, amplitude; ns, non-significant; HFOV, high-frequency oscillatory ventilation; paw, airway pressure; SD, standard deviation.
aA significant increase was observed during the first 2 hours of the study (p = 0.03). During the remainder of the study, there were 
no significant variations.
bMean arterial pressure was stable during the entire study.
cHeart rate significantly decreased from the 12th hour of the study (p < 0.05 for 24-hour and 48-hour comparisons).
300
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Figure 1 Changes in mean Sat.O2/FiO2 ratio, FiO2, PCO2, and pH during the different periods of HFOV. (A) *p < 0.05, at initiation 
versus 2 hours; Sat.O2/FiO2 ratio became significantly higher 2 hours after starting HFOV, and a significant increase was observed 
until 24 hours of HFOV. (B) †p < 0.05 at initiation versus 2 hours, at 6 versus 2 hours, at 12 hours versus 6 hours, and at 24 hours 
versus 12 hours; FiO2 was lower immediately after starting HFOV. Along the 24 hours of the study, significant lower levels of FiO2 
were reached. (C) ‡p < 0.05 at initiation versus 2 hours, and at 6 hours versus 2 hours; PCO2 significantly decreased at 2 hours and 
6 hours of HFOV. Thereafter it remained within reference ranges. (D) §p < 0.05 at initiation versus 2 hours, and at 6 hours versus 2 
hours; pH significantly rose during the first 6 hours of HFOV, when normal values were reached. FiO2, fraction of inspired oxygen; 
PCO2, partial pressure of carbon dioxide; Sat.O2, transcutaneous oxygen saturation.
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Discussion
In this study, it is reported one of the largest single-center 
pediatric studies in which HFOV was a safe modality 
for ventilating young patients with acute lung disease 
associated with heterogeneous clinical diagnosis, such as 
pneumonia, bronchiolitis, ARDS, and sepsis. In all patients, 
a statistically significant improvement in pH and PCO2 
values, together with a decrease in FiO2 and an increase of 
the Sat.O2/FiO2 ratio, demonstrated the efficacy of HFOV on 
ventilation and oxygenation. These effects were registered 
after 2 hours of HFOV. Similar results with HFOV have also 
been reported in pediatric and adult populations.8-9,17 
Some of the patients who started HFOV presented small 
airway disease due to underlying bronchiolitis, in which 
PCO2 clearance is a main problem. In this subgroup of 
patients, when HFOV was started, not only was hypoxemia 
present but also hypercapnia was moderate or severe. In 
this study’s population, patients with bronchiolitis were 
mainly infants aged less than 3 months with minimal 
physiological time constant, so an approach of high volume 
and low respiratory rate was not used. HFOV proved to be 
very efficient in patients with diffuse alveolar disease or 
with increased airway resistance and hyperinflation. Slee-
Wijffels et al. reported a single-center experience, which 
included 17 patients with small airway disease who were 
successfully ventilated on HFOV.10
In this study, maximum parameters in CMV were not 
aggressive, since HFOV was used as an early intervention 
strategy in the course of disease and when lung recruitment 
was needed. The optimal timing to initiate HFOV is not yet 
defined, and different approaches can be found in literature. 
Fedora et al. reported a survival benefit in children with 
ARDS ventilated in HFOV during the first 24 hours of 
mechanical ventilation.18 In their study, the mean length of 
CMV prior to HFOV was 8.8 hours in the early intervention 
group, and 133.3 hours in the late intervention group.18 In 
the study by Slee-Wijffels et al., the median length of CMV 
was 29.5 hours in the survivor group and 63 hours in the 
non-survivor group.10 In a multicenter experience reported 
by Arnold JH et al., the duration of CMV before HFOV was 
found to have a significant relationship with outcome.19 In 
the present study, HFOV was the first invasive ventilation 
option in 12 patients, and in the others CMV was applied for 
a short period of time (median duration 12 hours). 
Although several oxygenation strategies, including HFOV, 
have been studied in patients with acute lung injury, most 
published studies refer to the adult population; their 
extrapolation to pediatric patients is not always feasible. 
To date, there is not enough evidence to recommend one 
strategy over another.20,21 In PICU, only one prospective 
study comparing HFOV and CMV was performed, and a 
statistically significant difference in mortality with HFOV 
could not be proved.8 
In this study, only three cases of air leak occurred during 
HFOV. However, a direct relationship between air leaks 
and HFOV could not be established. All three patients had 
severe ARDS, which could also be responsible for the air 
leak. In the study by Ben Jaballah N et al., HFOV did not 
cause any new air leak syndrome; Arnold JH et al. found 
that HFOV was not associated with a higher number of air 
leaks when compared to CMV.8,22 Other problems found 
during HFOV were transitory hypoxemia and bradycardia 
associated with endotracheal tube suction. During HFOV, 
increased secretions were produced. To avoid transitory 
hemodynamic instability and loss of alveolar recruitment, 
suction should be performed with closed loops and a 
slight increase in Paw (3-5 cmH2O). Also, attention to the 
vibration pattern may be important to detect endotracheal 
tube obstruction. This approach may have contributed to 
the low number of complications presented in this article.
During the study period, patients remained 
hemodynamically stable without significant oscillations in 
blood pressure and heart rate. Inotropics were prescribed 
in about 65% of the patients, which could be related to 
the severity of the underlying disease or possibly to HFOV. 
However, since an invasive hemodynamic study was not 
performed, a direct relation with HFOV could not be 
established. In the study by David M et al., transition to 
HFOV was related to a statistically significant increase in 
right atrial pressure and pulmonary occlusion pressure, 
together with a decrease in cardiac index.23 However, as 
Table 3 Comparison of maximal ventilatory parameters during HFOV between the group of survivors and non-survivors.
Parameters Maximal HFOV settings
 Survivors Non-survivors p-value
Maximal ventilator settings   
MAP (cmH2O) 19.8±5 24.3±6 0.008
FiO2  0.7±0.2 0.9±0.2 0.023
delta-p 51±15 67±15 0.001
Frequency (Hz) 11±1  9.5±1 0.002
Minimal frequency (Hz) 10±1.4 8±1 < 0.001
delta-p, amplitude; FiO2, fraction of inspired oxygen; HFOV, high-frequency oscillatory ventilation; MAP, mean airways pressure.
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in the present study, they did not observe hemodynamic 
instability in their patients, and after transition to HFOV 
changes in vasoactive or inotropic support were not 
performed.22
In the present study, the overall survival rate was 
83.8%, higher than others reported in the literature 
(between 45% and 75%).21,24 This difference could be due 
to the variety of underlying diseases that led to HFOV, 
and also probably due to the early institution of this 
ventilatory strategy. 
Persistent hypoxemia at 48 hours of HFOV was associated 
with a poor prognosis. There were no other independent 
mortality factors. 
The retrospective design and data collection were the 
major limitations of the present study. Patients were 
not randomly selected, and data were collected relying 
on nurses and medical records. Blood gases were mainly 
obtained from capillaries, thus oxygen partial pressure 
could not be calculated. A recently validated ratio in 
the pediatric population (Sat.O2/FiO2) was used to study 
improvements in oxygenation.16 This index is important 
for monitoring oxygenation in situations where PaO2 is not 
obtained.
Conclusion
HFOV is an efficient ventilation strategy in a variety 
of clinical settings, and it is associated with a rapid 
improvement in oxygenation and ventilation. Lung 
injury associated with alveolar disease or with increased 
airway resistance was safely treated with HFOV. Minimal 
complications and high survival rates contributed to the 
successful use of HFOV. 
It can be concluded that an approach using HFOV instead 
of aggressive CMV appears to be safe. 
An adequate HFOV protocol remains important in order 
to avoid complications. Future randomized controlled 
trials comparing conventional ventilation and HFOV will be 
crucial to delineate the role of HFOV as an early strategy 
in lung recruitment. 
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